Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Epigenomics

DB:ECX
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ECX
DB
€49M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, and Asia. The last earnings update was 141 days ago. More info.


Add to Portfolio Compare Print
  • Epigenomics has significant price volatility in the past 3 months.
ECX Share Price and Events
7 Day Returns
-2.4%
DB:ECX
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-48.8%
DB:ECX
-7.4%
DE Biotechs
-14.2%
DE Market
ECX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Epigenomics (ECX) -2.4% -11.6% -27.8% -48.8% -79.4% -81.4%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • ECX underperformed the Biotechs industry which returned -7.4% over the past year.
  • ECX underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
ECX
Industry
5yr Volatility vs Market
Related Companies

ECX Value

 Is Epigenomics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Epigenomics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Epigenomics.

DB:ECX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:ECX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 30%) (1.99%))
1.042
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.04
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.042 * 5.44%)
5.28%

Discounted Cash Flow Calculation for DB:ECX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Epigenomics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:ECX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 5.28%)
2020 -14.10 Analyst x2 -13.39
2021 -12.85 Analyst x2 -11.59
2022 -8.35 Analyst x2 -7.16
2023 -1.30 Analyst x2 -1.06
2024 4.70 Analyst x2 3.63
2025 7.58 Est @ 61.33% 5.57
2026 10.83 Est @ 42.81% 7.55
2027 14.06 Est @ 29.85% 9.32
2028 16.98 Est @ 20.78% 10.69
2029 19.43 Est @ 14.43% 11.62
Present value of next 10 years cash flows €15.00
DB:ECX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €19.43 × (1 + -0.39%) ÷ (5.28% – -0.39%)
€341.51
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €341.51 ÷ (1 + 5.28%)10
€204.18
DB:ECX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €15.00 + €204.18
€219.18
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €219.18 / 47.13
€4.65
DB:ECX Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:ECX represents 0.98558x of XTRA:ECX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.98558x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 4.65 x 0.98558
€4.58
Value per share (EUR) From above. €4.58
Current discount Discount to share price of €1.03
= -1 x (€1.03 - €4.58) / €4.58
77.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Epigenomics is available for.
Intrinsic value
>50%
Share price is €1.03 vs Future cash flow value of €4.58
Current Discount Checks
For Epigenomics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Epigenomics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Epigenomics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Epigenomics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Epigenomics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:ECX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in EUR €-0.39
XTRA:ECX Share Price ** XTRA (2020-04-08) in EUR €1.04
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Epigenomics.

DB:ECX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:ECX Share Price ÷ EPS (both in EUR)

= 1.04 ÷ -0.39

-2.68x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Epigenomics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Epigenomics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Epigenomics's expected growth come at a high price?
Raw Data
DB:ECX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.68x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
55.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Epigenomics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Epigenomics's assets?
Raw Data
DB:ECX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in EUR €0.25
XTRA:ECX Share Price * XTRA (2020-04-08) in EUR €1.04
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:ECX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:ECX Share Price ÷ Book Value per Share (both in EUR)

= 1.04 ÷ 0.25

4.2x

* Primary Listing of Epigenomics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Epigenomics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Epigenomics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Epigenomics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ECX Future Performance

 How is Epigenomics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Epigenomics expected to grow at an attractive rate?
  • Epigenomics's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Epigenomics's earnings growth is expected to exceed the Germany market average.
  • Epigenomics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:ECX Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:ECX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 55.5%
DB:ECX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 59.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:ECX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:ECX Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 104 30 2
2023-12-31 64 21 2
2022-12-31 32 0 2
2021-12-31 15 -17 -11 2
2020-12-31 6 -17 -14 2
2020-04-09
2019-12-31 1 -14 -12 2
DB:ECX Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-09-30 1 -14 -14
2019-06-30 1 -14 -14
2019-03-31 2 -12 -12
2018-12-31 2 -10 -13
2018-09-30 2 -10 -11
2018-06-30 2 -9 -10
2018-03-31 2 -11 -11
2017-12-31 2 -10 -10
2017-09-30 3 -12 -9
2017-06-30 3 -14 -10
2017-03-31 4 -12 -9
2016-12-31 4 -13 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Epigenomics's earnings are expected to grow significantly at over 20% yearly.
  • Epigenomics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:ECX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Epigenomics Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ECX Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 -0.27 -0.20 -0.34 2.00
2020-12-31 -0.34 -0.31 -0.37 2.00
2020-04-09
2019-12-31 -0.34 -0.30 -0.37 2.00
DB:ECX Past Financials Data
Date (Data in EUR Millions) EPS *
2019-09-30 -0.39
2019-06-30 -0.43
2019-03-31 -0.42
2018-12-31 -0.47
2018-09-30 -0.47
2018-06-30 -0.40
2018-03-31 -0.47
2017-12-31 -0.44
2017-09-30 -0.39
2017-06-30 -0.46
2017-03-31 -0.43
2016-12-31 -0.55

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Epigenomics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Epigenomics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Epigenomics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ECX Past Performance

  How has Epigenomics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Epigenomics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Epigenomics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Epigenomics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Epigenomics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Epigenomics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Epigenomics Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ECX Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 1.07 -13.96 9.53 7.61
2019-06-30 1.44 -14.33 9.68 7.24
2019-03-31 1.56 -12.49 9.28 6.46
2018-12-31 1.53 -12.69 8.70 6.42
2018-09-30 2.31 -11.37 7.87 5.64
2018-06-30 2.11 -9.54 6.55 4.86
2018-03-31 1.89 -11.09 7.91 4.81
2017-12-31 1.86 -10.24 8.04 4.33
2017-09-30 2.66 -8.82 8.44 3.99
2017-06-30 3.17 -10.02 9.64 4.28
2017-03-31 4.19 -9.21 9.04 4.05
2016-12-31 4.20 -11.16 10.25 5.12
2016-09-30 3.18 -10.91 9.20 4.75
2016-06-30 2.78 -10.98 8.61 5.27
2016-03-31 2.01 -10.15 7.01 5.68
2015-12-31 2.08 -8.99 5.15 5.76
2015-09-30 1.74 -10.98 5.70 6.76
2015-06-30 1.55 -10.41 5.40 6.37
2015-03-31 1.47 -9.78 5.15 5.63
2014-12-31 1.51 -8.85 4.91 4.69
2014-09-30 1.72 -8.09 4.66 4.44
2014-06-30 1.70 -8.12 4.60 4.44
2014-03-31 1.64 -7.94 4.53 4.60
2013-12-31 1.59 -7.41 4.51 4.38
2013-09-30 1.33 -8.01 3.86 5.31
2013-06-30 1.34 -9.83 4.55 6.53

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Epigenomics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Epigenomics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Epigenomics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Epigenomics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Epigenomics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ECX Health

 How is Epigenomics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Epigenomics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Epigenomics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Epigenomics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Epigenomics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Epigenomics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Epigenomics Company Filings, last reported 6 months ago.

DB:ECX Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 8.93 0.00 6.28
2019-06-30 11.70 0.00 9.14
2019-03-31 15.79 0.00 12.87
2018-12-31 18.61 0.00 17.14
2018-09-30 2.38 6.96 6.63
2018-06-30 5.04 6.82 9.38
2018-03-31 7.69 6.67 11.21
2017-12-31 10.58 6.54 13.73
2017-09-30 13.01 6.41 16.88
2017-06-30 8.47 0.00 7.68
2017-03-31 12.27 0.00 10.73
2016-12-31 14.42 0.00 12.28
2016-09-30 6.85 0.54 7.27
2016-06-30 9.24 0.54 13.22
2016-03-31 5.17 0.64 8.06
2015-12-31 7.10 1.07 8.58
2015-09-30 7.40 1.18 9.72
2015-06-30 8.66 1.39 10.66
2015-03-31 4.37 1.71 6.44
2014-12-31 6.11 1.93 7.51
2014-09-30 3.03 2.25 3.91
2014-06-30 4.93 2.18 6.77
2014-03-31 6.75 1.97 8.43
2013-12-31 6.46 1.93 7.97
2013-09-30 3.81 0.26 2.63
2013-06-30 5.36 0.00 3.58
  • Epigenomics has no debt.
  • Epigenomics has no debt compared to 5 years ago when it was 73.4%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Epigenomics has less than a year of cash runway based on current free cash flow.
  • Epigenomics has less than a year of cash runway if free cash flow continues to grow at historical rates of 10.8% each year.
X
Financial health checks
We assess Epigenomics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Epigenomics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ECX Dividends

 What is Epigenomics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Epigenomics dividends. Estimated to be 0% next year.
If you bought €2,000 of Epigenomics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Epigenomics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Epigenomics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:ECX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:ECX Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2020-04-09
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Epigenomics has not reported any payouts.
  • Unable to verify if Epigenomics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Epigenomics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Epigenomics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Epigenomics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Epigenomics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Epigenomics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Epigenomics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ECX Management

 What is the CEO of Epigenomics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Greg Hamilton
COMPENSATION €962,253
AGE 49
TENURE AS CEO 3.8 years
CEO Bio

Mr. Gregory Hamilton, also known as Greg, has been the Chief Executive Officer and Member of Executive Board at Epigenomics AG since July 1, 2016. Mr. Hamilton has over 20 years of management experience in molecular diagnostics, manufacturing and professional service industries. He is responsible for multiple FDA-cleared products including a Human Papilloma Virus (HPV) High Risk Screening assay and the first ever cleared HPV genotyping assay. He has held senior management positions in the U.S. molecular diagnostics industry. Mr. Hamilton served as the Chief Executive Officer of AltheaDx, Inc. since February 2014. Mr. Hamilton served as President of AltheaDx, Inc. from May 2013 to February 2014. He served as Chief Operating Officer of USA and Chief Financial Officer of USA at Enigma Diagnostics Limited. Mr. Hamilton joined the Enigma team after serving as Vice President of Operations, Planning and Analysis for Hologic, Inc.'s business unit specialising in women's healthcare products. He served as Vice President of Finance and Operations at Third Wave Technologies Inc. Prior to Hologic, Mr. Hamilton served as Chief Financial Officer at iLeo. He served as a Director of AltheaDx, Inc. since May 2013. Mr. Hamilton graduated from Purdue University in 1992 with a Bachelor of Science degree in finance and earned an MBA in finance, strategy and entrepreneurship from the University of Chicago Booth School of Business.

CEO Compensation
  • Greg's compensation has increased whilst company is loss making.
  • Greg's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Epigenomics management team in years:

3
Average Tenure
49
Average Age
  • The tenure for the Epigenomics management team is about average.
Management Team

Greg Hamilton

TITLE
CEO & Member of the Executive Board
COMPENSATION
€962K
AGE
49
TENURE
3.8 yrs

Jorge Garces

TITLE
President
COMPENSATION
€935K
AGE
47
TENURE
2.3 yrs

Albert Weber

TITLE
Executive VP of Finance & Member of the Executive Board
COMPENSATION
€422K
AGE
56
TENURE
2.3 yrs

Peter Vogt

TITLE
Vice President of Corporate Communications & Investor Relations

Noel Doheny

TITLE
Chief Executive Officer of Epigenomics Inc.
TENURE
8.9 yrs

Frederic Hilke

TITLE
Investor Relations Officer
Board of Directors Tenure

Average tenure and age of the Epigenomics board of directors in years:

5.4
Average Tenure
70
Average Age
  • The tenure for the Epigenomics board of directors is about average.
Board of Directors

Heino von Prondzynski

TITLE
Chairman of the Supervisory Board
COMPENSATION
€102K
AGE
70
TENURE
7.9 yrs

Günther Reiter

TITLE
Vice-Chairman of the Supervisory Board
COMPENSATION
€52K
TENURE
5.4 yrs

Ann Kessler

TITLE
Deputy Chairwoman of the Supervisory Board
COMPENSATION
€52K
AGE
75
TENURE
7.9 yrs

Helge Lubenow

TITLE
Member of the Supervisory Board
COMPENSATION
€47K
TENURE
3.9 yrs

Franz Walt

TITLE
Member of the Supervisory Board
AGE
60
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Epigenomics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Epigenomics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ECX News

Simply Wall St News

Is Epigenomics AG (FRA:ECX) Excessively Paying Its CEO?

First, this article will compare CEO compensation with compensation at similar sized companies. … See our latest analysis for Epigenomics How Does Greg Hamilton's Compensation Compare With Similar Sized Companies? … We compared the total CEO remuneration paid by Epigenomics AG, and compared it to remuneration at a group of similar sized companies.

Simply Wall St -

What Kind Of Shareholder Appears On The Epigenomics AG's (FRA:ECX) Shareholder Register?

Insider Ownership Of Epigenomics The definition of company insiders can be subjective, and does vary between jurisdictions. … Private Company Ownership We can see that Private Companies own 12%, of the shares on issue. … Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual.

Simply Wall St -

If You Had Bought Epigenomics (FRA:ECX) Stock Three Years Ago, You'd Be Sitting On A 63% Loss, Today

The more recent news is of little comfort, with the share price down 46% in a year. … So the share price itself impacts the value of the shares (as it determines the cost of capital). … We'd venture that shareholders are concerned about the need for more capital, because the share price has dropped 28% per year, over 3 years.

Simply Wall St -

Who Really Owns Epigenomics AG (FRA:ECX)?

In this article, I will take a quick look at Epigenomics AG’s (FRA:ECX) recent ownership structure – an unconventional investing subject, but an important one. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

Who Are Epigenomics AG's (FRA:ECX) Major Shareholders?

Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … Private Company Ownership Potential investors in ECX should also look at another important group of investors: private companies, with a stake of 18.60%, who are primarily invested because of strategic and capital gain interests. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.

Simply Wall St -

Want To Invest In Epigenomics AG (FRA:ECX)? Here's How It Performed Lately

After looking at Epigenomics AG's (DB:ECX) latest earnings announcement (30 September 2017), I found it useful to revisit the company's performance in the past couple of years and assess this against the most recent figures. … View our latest analysis for Epigenomics Did ECX's recent earnings growth beat the long-term trend and the industry? … For the purpose of this commentary, I like to use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data.

Simply Wall St -

ECX Company Info

Description

Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, and Asia. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool provides set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of colorectal and lung cancers. In addition, the company engages in the research and identification of additional DNA methylation biomarkers for prostate, bladder, breast, and ovarian cancers. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Details
Name: Epigenomics AG
ECX
Exchange: DB
Founded: 1998
€49,015,039
47,129,846
Website: http://www.epigenomics.com
Address: Epigenomics AG
Geneststrasse 5,
Berlin,
Berlin, 10829,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA ECX Registered Shares XETRA Trading Platform DE EUR 10. Sep 2014
DB ECX Registered Shares Deutsche Boerse AG DE EUR 10. Sep 2014
LSE 0QXH Registered Shares London Stock Exchange GB EUR 10. Sep 2014
BATS-CHIXE ECXD Registered Shares BATS 'Chi-X Europe' GB EUR 10. Sep 2014
ETLX ECX Registered Shares Eurotlx IT EUR 10. Sep 2014
OTCPK EPGN.Y SPONSORED ADR Pink Sheets LLC US USD 10. Jul 2013
OTCPK EPGN.F Common Shares Pink Sheets LLC US USD 19. Jul 2004
Number of employees
Current staff
Staff numbers
42
Epigenomics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 00:02
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/07
Last earnings filing: 2019/11/20
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.